It is another nightmare year for Casdin Capital.
The life sciences hedge fund was down 32 percent in the first quarter alone in a generally rough period for much of the sector. As a result, 2025 could be Casdin’s third disastrous year in the past five, making it nearly impossible to predict when or if the firm will ever hit its high-water mark.
The
